ReviewMolecular therapy : the journal of the American Society of Gene Therapy2022
Multipurposing CARs: Same engine, different vehicles.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Natural killer cells against viral infection: from basic biology to immunotherapy.Precision clinical medicine · 2026Review
- Focused ultrasound as a therapeutic adjunct in pancreatic cancer: from thermal and mechanical effects to immune modulation.Ultrasonography (Seoul, Korea) · 2026Article
- Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases.Precision clinical medicine · 2026Review
- Cell therapy in sarcoma: current landscape and future directions.Journal for immunotherapy of cancer · 2026Review
- STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer.Journal of gastroenterology · 2025Article
- Engineering and targeting potential of CAR NK cells in colorectal cancer.Chinese medical journal · 2025Review
- From myth to bedside: a scoping review of the applications of the chimeric antigen receptor in rheumatology.Clinical and experimental medicine · 2025Article
- NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand.iScience · 2025Article
- CAR-γδ T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond.Frontiers in immunology · 2025Review
- CAR-T cell therapy as an approach for pediatric hematological malignancies in regenerative therapy: Current status and clinical outcomes.BioImpacts : BI · 2025Review
- CAR-iNKT cells: redefining the frontiers of cellular immunotherapy.Frontiers in immunology · 2025Review
- CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.Frontiers in immunology · 2025Article
- Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.Journal for immunotherapy of cancer · 2024Article
- Engineering Improved CAR T Cell Products with A Multi-Cytokine Particle Platform for Hematologic and Solid Tumors.Advanced healthcare materials · 2024Article
- Review
- Review
- Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response.British journal of cancer · 2023Review
- The role of MSCs and CAR-MSCs in cellular immunotherapy.Cell communication and signaling : CCS · 2023Review
- A novel TREM1/DAP12-based multiple chain CAR-T cell targets PTK7 in ovarian cancer therapy.Medical oncology (Northwood, London, England) · 2023Article
- New cell sources for CAR-based immunotherapy.Biomarker research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
T cells genetically engineered to recognize and eliminate tumor cells through synthetic chimeric antigen receptors (CARs) have demonstrated remarkable clinical efficacy against B cell leukemia over the past decade. This therapy is a form of highly personalized medicine that involves genetically modifying a patient's T cells to recognize and kill cancer cells. With the FDA approval of 5 CAR T cell products, this approach has been validated as a powerful new drug in the therapeutic armamentarium against cancer. Researchers are now studying how to expand this technology beyond its use in conventional polyclonal αβ T cells to address limitations to the current therapy in cancer and applications beyond it. Considering the specific characteristics of immune cell from diverse lineages, several preclinical and clinical studies are under way to assess the advantages of CAR-redirected function in these cells and apply the lessons learned from CAR T cell therapy in cancer to other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.